This webpage contains promotional information regarding Napp products. The content has been reviewed ny Napp to ensure compliance with the ABPI code of practice for the pharmaseutical industry.
Invokana reduces the risk of major CV events over the long term (6.5 years).1
All-cause mortality was the first secondary endpoint in the pre-specified hypothesis testing sequence.1
Because analysis of this endpoint failed to show superiority for Invokana, hypothesis testing could not be carried out for the other secondary endpoints.1
ARR: Absolute Risk Reduction; CANVAS: Canagliflozin Cardiovascular Assessment Study; CI: Confidence Interval; CV: Cardiovascular; HHF: Hospitalisation for Heart Failure; HR: Hazard Ratio; MACE: Major Adverse Cardiovascular Events; SoC: Standard of Care; T2DM: Type 2 Diabetes Mellitus.